Aastrom surges after acquiring Sanofi’s cell therapies

John Carroll A little more than a year after reorganizing the company and slashing staff in the wake of a Phase III failure, Ann Arbor, MI-based Aastrom Biosciences has acquired Sanofi's ...

Docs that just say no to drug samples slash brand prescribing big-time, study finds

Tracy Staton A new JAMA Dermatology study shows a huge difference in brand-name scripts written by physicians who turn down drug samples–a 62-percentage-point difference, ...

Novartis near to wrapping up $1.7B sale of part-owned patchmaker LTS Lohmann

Tracy Staton It's been almost a yearlong contest, but a deal for patchmaker LTS Lohmann appears to be nearing the finish line. The private equity firm Nordic Capital is likely to ...

FDA lifts its hold on Juno’s cutting-edge cancer drug after deaths trigger delay

John Carroll The FDA has lifted a clinical hold placed on a study at Memorial Sloan-Kettering of Juno Therapeutics' cutting-edge approach to treating cancer using genetically tailored ...

Nasdaq volatility delays IPO, Almirall pulls drug over price, Topotarget to merge as PDUFA nears

Nick Paul Taylor Welcome to this week's edition of our EuroBiotech Report, in which we have news of how the rise and fall of U.S. biotech and med tech stocks is shaping decisions ...

Gardasil dose reduction could boost EU sales for Merck-Sanofi joint venture

Tracy Staton Now that the European Commission has officially approved a two-dose Gardasil regimen for early teens, Merck and Sanofi–who market the HPV vaccine in Europe through ...

GlaxoSmithKline wins an FDA nod for its GLP-1 diabetes drug albiglutide

Damian Garde After a three-month delay pushed pause on its commercial plans, GlaxoSmithKline has secured FDA approval for albiglutide, a new diabetes treatment that will contend for ...

Generics makers ask SCOTUS to let them proceed with Copaxone copies

Carly Helfand Teva wants generics makers to hold off on launching their copies of multiple sclerosis drug Copaxone until the Supreme Court hears its appeal in a patent fight over the ...

ThromboGenics is picking between billion-dollar bids, report says

Damian Garde Just over a month into its search for "strategic options," ThromboGenics has rounded up a bevy of high-dollar offers that could value the company at as much as ...

Lupin recalls more Suprax on purity problems, adding to Indian pharma’s quality questions

Tracy Staton In the latest black eye for India's pharma industry, Lupin is recalling some 10,000 bottles of its Suprax antibiotic in the U.S. The pills fell short of standards for ...

Novartis backs away from once-ambitious RNAi research

Tracy Staton Novartis is shuttering a large part of its once-ambitious RNAi research effort in Boston, FierceBiotech has learned. FiercePharma News

Merck bags FDA approval for its grass pollen pill

Damian Garde Merck picked up an expected FDA approval for the first of three immunotherapies in its allergy pipeline, gearing up to launch a grass pollen-fighting treatment with hopes ...
Page 4 of 512345
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS